Trial Profile
A Study to Assess the Absorption of Apixaban (BMS-562247) Sprinkle Capsules Compared With Tablets in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jan 2020
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Apixaban
- Indications Acute coronary syndromes; Deep vein thrombosis; Heparin-induced thrombocytopenia and thrombosis syndrome; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 30 Jul 2018 Status changed from recruiting to completed.
- 08 Jun 2018 Planned End Date changed from 28 May 2018 to 29 Jun 2018.
- 08 Jun 2018 Planned primary completion date changed from 25 May 2018 to 29 Jun 2018.